The challenge of SensUs 2021 was to develop a biosensor to detect the acute respiratory virus influenza A. Influenza viruses are known to mutate quickly, contributing to pandemic-type situations in society sooner rather than later. As the Covid-19 pandemic has shown, rapid testing of patients is crucial to contain the spread of viruses.
The challenge of SensUs 2020 was to develop a biosensor for the measurement of unbound Valproate. This is a biological drug that is prescribed to patients suffering from epilepsy. Epilepsy is a chronic noncommunicable disease of the brain that affects people of all ages. Around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally.
For this years competition, we will create a biosensor to detect an antibiotic called vancomycin. The detection and measurement of vancomycin needs to be efficient and not harmful for patients.
Heart failure is a very important public health problem in both developed and developing countries with a prevalence of about 1% of the population. This year, SensUs features NT-proBNP as its target molecule, which is a key biomarker for heart failure. But what is NT-proBNP and why is it important? And how does NT-proBNP relate to heart failure? This video explains how the heart functions, what happens when it fails to function, and why NT-proBNP is a very useful molecule to measure with a small and rapid biosensor.
1.7 Million people in the Netherlands suffer from chronic kidney damage and early detection is necessary to prevent for worse. Creatinine is one indicator for kidney diseases and so T.E.S.T. developed a biosensor prototype to determine creatinine concentrations in blood plasma. In this movie the potential of this prototype is shown, keeping in mind that there are still some obstacles that need to be overcome.